Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...
Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
Cystatin C (CysC) is an independent risk factor for adverse outcomes in patients with HF across the ejection fraction (EF) spectrum.
Patients with symptomatic heart failure (HF) and normal to near-normal ejection fraction (EF) have different pathophysiological alterations compared with those with HF and low EF, and current ...
2d
Distinct metabolic signature found in patients with heart failure with preserved ejection fraction
What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...
Please provide your email address to receive an email when new articles are posted on . Among patients with asymptomatic aortic valve stenosis, elevated acceleration time/ejection time ratio was ...
EAT index measured by CMR may identify high-risk HFpEF patients and predict outcomes. Learn more about its role in risk ...
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...
Population-based studies report that the majority of elderly patients with heart failure have a normal ejection fraction (HF-NEF) and a history of hypertension. Left ventricular diastolic dysfunction, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results